Evidence map›Paper›PMID 41258323›Full record

ArticleNeurology and therapy2026

Efgartigimod as Fast-Acting Rescue Therapy in Very Late-Onset Myasthenia Gravis.

Nicasio Rini, Flora D'Amico, Valentina Portera, Filippo Brighina, Vincenzo Di Stefano

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nicasio RiniDepartment of Biomedicine, Neuroscience, and Advanced Diagnostic (BIND), University of Palermo, Via del Vespro 143, 90129, Palermo, Italy.
Flora D'AmicoDepartment of Biomedicine, Neuroscience, and Advanced Diagnostic (BIND), University of Palermo, Via del Vespro 143, 90129, Palermo, Italy.
Valentina PorteraDepartment of Biomedicine, Neuroscience, and Advanced Diagnostic (BIND), University of Palermo, Via del Vespro 143, 90129, Palermo, Italy.
Filippo BrighinaDepartment of Biomedicine, Neuroscience, and Advanced Diagnostic (BIND), University of Palermo, Via del Vespro 143, 90129, Palermo, Italy.
Vincenzo Di StefanoDepartment of Biomedicine, Neuroscience, and Advanced Diagnostic (BIND), University of Palermo, Via del Vespro 143, 90129, Palermo, Italy. vincenzo.distefano07@unipa.it.ORCID http://orcid.org/0000-0001-9805-1655

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myasthenic crisis (MC) is a potentially fatal complication of myasthenia gravis (MG), often requiring intensive care and rescue therapies such as intravenous immunoglobulin (IVIG) and corticosteroids. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, offers a novel approach by selectively reducing circulating pathogenic IgG. We describe a 77-year-old man with anti-AChR-positive generalized MG who developed a severe MC, with little response to IVIG and high-dose corticosteroids. Intravenous efgartigimod was administered as rescue therapy with rapid and sustained clinical improvement. This case supports the utility of efgartigimod in MC unresponsive to conventional therapies, including in older patients with significant comorbidities.

Indexed as

AChR antibodiesEfgartigimodFcRn inhibitionMyasthenic crisisRescue therapyVery late-onset myasthenia gravis

Identifiers

PMID41258323
PMCPMC12804559

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.